NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 216 filers reported holding NEKTAR THERAPEUTICS in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37 | +2.8% | 61,886 | 0.0% | 0.00% | – |
| Q2 2023 | $36 | -16.3% | 61,886 | 0.0% | 0.00% | – |
| Q1 2023 | $43 | -69.3% | 61,886 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $140 | -99.9% | 61,886 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $198,000 | -37.1% | 61,886 | +5.8% | 0.00% | -33.3% |
| Q1 2022 | $315,000 | -50.0% | 58,500 | +25.5% | 0.00% | -50.0% |
| Q4 2021 | $630,000 | +72.6% | 46,600 | +129.6% | 0.01% | +100.0% |
| Q3 2021 | $365,000 | +4.9% | 20,300 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $348,000 | -14.3% | 20,300 | 0.0% | 0.00% | -25.0% |
| Q1 2021 | $406,000 | +3.8% | 20,300 | -11.7% | 0.00% | 0.0% |
| Q4 2020 | $391,000 | -12.3% | 23,000 | -14.5% | 0.00% | -20.0% |
| Q3 2020 | $446,000 | -28.4% | 26,900 | 0.0% | 0.01% | -28.6% |
| Q2 2020 | $623,000 | +29.8% | 26,900 | 0.0% | 0.01% | 0.0% |
| Q1 2020 | $480,000 | -24.6% | 26,900 | -8.8% | 0.01% | 0.0% |
| Q4 2019 | $637,000 | +108.2% | 29,500 | +75.6% | 0.01% | +75.0% |
| Q3 2019 | $306,000 | -48.8% | 16,800 | 0.0% | 0.00% | -42.9% |
| Q2 2019 | $598,000 | +6.0% | 16,800 | 0.0% | 0.01% | 0.0% |
| Q1 2019 | $564,000 | +2.2% | 16,800 | 0.0% | 0.01% | -12.5% |
| Q4 2018 | $552,000 | -48.0% | 16,800 | -3.4% | 0.01% | -38.5% |
| Q3 2018 | $1,061,000 | -28.7% | 17,400 | -43.0% | 0.01% | -27.8% |
| Q2 2018 | $1,489,000 | -76.4% | 30,500 | -48.7% | 0.02% | -76.3% |
| Q1 2018 | $6,312,000 | +124.9% | 59,405 | +26.4% | 0.08% | +130.3% |
| Q4 2017 | $2,807,000 | +148.8% | 47,000 | 0.0% | 0.03% | +135.7% |
| Q3 2017 | $1,128,000 | +22.7% | 47,000 | 0.0% | 0.01% | +16.7% |
| Q2 2017 | $919,000 | -16.7% | 47,000 | 0.0% | 0.01% | -14.3% |
| Q1 2017 | $1,103,000 | +91.2% | 47,000 | 0.0% | 0.01% | +100.0% |
| Q4 2016 | $577,000 | -32.7% | 47,000 | -5.8% | 0.01% | -36.4% |
| Q3 2016 | $857,000 | +45.0% | 49,900 | +20.2% | 0.01% | +37.5% |
| Q2 2016 | $591,000 | +3.5% | 41,500 | 0.0% | 0.01% | +14.3% |
| Q1 2016 | $571,000 | -18.3% | 41,500 | 0.0% | 0.01% | -22.2% |
| Q4 2015 | $699,000 | +53.6% | 41,500 | 0.0% | 0.01% | +50.0% |
| Q3 2015 | $455,000 | +42.6% | 41,500 | +62.7% | 0.01% | +50.0% |
| Q2 2015 | $319,000 | – | 25,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |